6-chloro-3-phenylpyrimidine-2,4(1H,3H)-dione | 5759-75-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-chloro-3-phenylpyrimidine-2,4(1H,3H)-dione
• 英文别名: 6-chloro-3-phenyl-1H-pyrimidine-2,4-dione；3-Phenyl-6-chlorouracil；6-chloro-3-phenyluracil；6-chloro-3-phenyl-1H-pyrimidine-2,4-dione；6-chloro-3-phenyl-2,4(1H,3H)-pyrimidinedione；1-Phenyl-4-chlor-uracil
• CAS: 5759-75-1
• 化学式: C₁₀H₇ClN₂O₂
• 分子量: 222.631
• InChiKey: MSQUPIDGZDKBJN-UHFFFAOYSA-N

物化性质

• 熔点：
  269-270 °C
• 密度：
  1.48±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  6-chloro-3-phenylpyrimidine-2,4(1H,3H)-dione 在 potassium carbonate 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 6-(4-chlorophenoxy)-5-(dimethylaminomethylidene)-3-phenylpyrimidine-2,4-dione
  参考文献：
  名称：

  Yoneda, Fumio; Hirayama, Ryiochi; Yamashita, Machiko, Journal of Heterocyclic Chemistry, 1982, vol. 19, p. 301 - 304

  摘要：

  DOI：
• 作为产物：
  描述：

  N-苯基巴比土酸 在 三氯氧磷 作用下， 生成 6-chloro-3-phenylpyrimidine-2,4(1H,3H)-dione
  参考文献：
  名称：

  Synthesis, biological active molecular design, and molecular docking study of novel deazaflavin–cholestane hybrid compounds

  摘要：

  Novel deazaflavin-cholestane hybrid compounds, 3',8'-disubstituted-5'-deazacholest-2,4-dieno[2,3g] pteridine-2',4'(3'H, 8'H)-diones, have been synthesized by condensation reaction between 6-(monosubstituted amino)-pyrimidin-2,4(1H,3H)-diones and 2-hydroxymethylenecholest-4-en-3-one in presence of p-toluenesulfonic acid monohydrate and diphenyl ether. The antitumor activities against human tumor cell lines (CCRF-HSB-2 and KB cells) have been investigated in vitro, and many of these compounds showed promising antitumor activities. Furthermore, molecular docking study using LigandFit within the software package Discovery Studio 1.7 was done for lead optimization of these compounds as potential PTK inhibitors. In general, all of the synthesized steroid-hybrid compounds showed good binding affinities into PTK (PDB code: 1t46). (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.07.089

文献信息

• AUTORECYCLING OXIDATION OF AMINES TO CARBONYL COMPOUNDS CATALYZED BY 3,4-DISUBSTITUTED 4-DEAZATOXOFLAVIN DERIVATIVES
  作者：Tomohisa Nagamatsu、Yuko Hashiguchi、Yoshiharu Sakuma、Fumio Yoneda

  DOI：10.1246/cl.1982.1309

  日期：1982.9.5

  3,4-Disubstituted 4-deazatoxoflavin derivatives (II) were prepared by the condensation of 6-(1-methylhydrazino)uracils (I) with appropriate α-diketones. The compounds II oxidized long-chain alkylamines such as n-octylamine and n-dodecylamine besides benzylamine and cyclohexylamine to yield the corresponding carbonyl compounds via imines, catalytically with a markedly high turnover number.

  3,4-二取代的 4-脱氮氧代黄素衍生物 (II) 是通过 6-(1-甲基肼基) 尿嘧啶 (I) 与适当的 α-二酮缩合制备的。除了苄胺和环己胺外，化合物II氧化长链烷基胺如正辛胺和正十二胺，通过亚胺产生相应的羰基化合物，催化转化率显着高。
• [EN] 3-FURANYL ANALOGS OF TOXOFLAVINE AS KINASE INHIBITORS<br/>[FR] ANALOGUES DE 3-FURANYLE DE TOXOFLAVINE EN TANT QU'INHIBITEURS DE KINASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2004007499A1

  公开（公告）日：2004-01-22

  The present invention concerns the compounds of formula (I) the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein m represents an integer being 0 or 1; n represents an integer being 0, 1 or 2; R1 represents C1-4alkyl, C1-4alkyl substituted with pyridinyl, phenyl, piperidinyl or piperidinyl substituted with C1-4-alkyloxycarbonyl; R2 represents hydrogen or C1-4 alkyl; R3 represents hydrogen or C1-4alkyl; or R2 and R3 taken together with the carbon atom to which they are attached form cyclopentyl or piperidinyl wherein said cyclopentyl or piperidinyl each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from C1-4alkyloxycarbonyl, phenylcarbonyl or -C(=NH)-NH2; R4 represents halo or C1-4alkyloxy; R5 represents Het2, C1-4alkyl substituted with one or where possible more substituents being selected from hydroxy, halo, Het3 or NR6R7, or C1-4alkyloxy substituted with one or where possible more substituents being selected from Het4 or -C(=O)-Het4; R6 and R7 are each independently selected from hydrogen, C1-4alkyl, Het5 or C1-4alkyl substituted with one or where possible more substituents being selected from hydroxy or Het5; Het2 represents piperazinyl; Het3 represents a heterocycle selected from morpholinyl, pyrrolidinyl, piperidinyl, or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from C1-4alkyl preferably methyl, aminosulfonyl, mono- or di(C1-4alkyl)aminosulfonyl, hydroxyC1 -4alkyloxyC1-4alkyl, C1-4alkyloxyC1-4alkyl or C1-4alkyloxy; Het4 represents a heterocycle selected from morpholinyl or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three C1-4alkyl substituents, preferably methyl; Het5 represents a heterocycle selected from pyridinyl, pyrrolidinyl or piperidinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from aminosulfonyl, C1-4alkyloxycarbonyl or mono- or di(C1-4alkyl)aminosulfonyl.

  本发明涉及具有式（I）的化合物，其N-氧化物形式，药用可接受的加合物盐及其立体化异构体形式，其中m代表为0或1的整数；n代表为0，1或2的整数；R1代表C1-4烷基，带有吡啶基，苯基，哌啶基或带有C1-4-烷氧羰基的C1-4烷基；R2代表氢或C1-4烷基；R3代表氢或C1-4烷基；或R2和R3与它们连接的碳原子一起形成环戊烷基或哌啶基，其中所述的环戊烷基或哌啶基各自可以选择性地被一个，或在可能的情况下，两个或三个取代基取代，每个取代基独立地选择自C1-4烷氧羰基，苯甲酰基或-C（=NH）-NH2；R4代表卤素或C1-4烷氧基；R5代表Het2，带有一个或在可能的情况下更多取代基的C1-4烷基，所选取的取代基包括羟基，卤素，Het3或NR6R7，或带有一个或在可能的情况下更多取代基的C1-4烷氧基，所选取的取代基包括Het4或-C（=O）-Het4；R6和R7各自独立选择自氢，C1-4烷基，Het5或带有羟基或Het5的C1-4烷基取代基；Het2代表哌嗪基；Het3代表从吗啉基，吡咯啉基，哌啶基或哌嗪基中选择的杂环，其中所述的单环杂环可以选择性地被一个，或在可能的情况下，两个或三个取代基取代，每个取代基独立地选择自C1-4烷基（最好是甲基），氨基磺酰基，单烷基或双烷基氨基磺酰基，羟基C1-4烷氧基C1-4烷基，C1-4烷氧基C1-4烷基或C1-4烷氧基；Het4代表从吗啉基或哌嗪基中选择的杂环，其中所述的单环杂环可以选择性地被一个，或在可能的情况下，两个或三个C1-4烷基取代基取代，最好是甲基；Het5代表从吡啶基，吡咯啉基或哌啶基中选择的杂环，其中所述的单环杂环可以选择性地被一个，或在可能的情况下，两个或三个取代基取代，每个取代基独立地选择自氨基磺酰基，C1-4烷氧羰基或单烷基或双烷基氨基磺酰基。
• Syntheses of 3-Substituted 1-Methyl-6-phenylpyrimido(5,4-e)-1,2,4-triazine-5,7(1H,6H)-diones (6-Phenyl Analogs of Toxoflavin) and Their 4-Oxides, and Evaluation of Antimicrobial Activity of Toxoflavins and Their Analogs.
  作者：Tomohisa NAGAMATSU、Hirofumi YAMASAKI、Takashi HIROTA、Masatoshi YAMATO、Yutaka KIDO、Motoo SHIBATA、Fumio YONEDA

  DOI：10.1248/cpb.41.362

  日期：——

  6-Phenyl analogs of toxoflavin (1-methyl-6-phenylpyrimido[5,4-e]-1,2,4-triazine-5,7(1H,6H)-diones ) (7a--f) and their 4-oxides (8a-f) were synthesized by nitrosative or nitrative cyclization of the aldehyde hydrazones (6a-f) of 6-(1-methylhydrazino)-3-phenyluracil (5). Both sets of compounds, 7a-f and 8a-f, gave the corresponding 1-demethyl derivatives (10a-f) upon treatment with nucleophiles such

  毒黄素的6-苯基类似物（1-甲基-6-苯基嘧啶[5,4-e] -1,2,4-三嗪-5,7（1H，6H）-二酮）（7a–f）及其4通过对6-（1-甲基肼基）-3-苯基尿嘧啶（5）的醛（6a-f）进行亚硝化或硝化环化反应合成α-氧化物（8a-f）。在加热下用亲核试剂如二甲基甲酰胺（DMF）和乙酸处理后，两组化合物7a-f和8a-f均得到相应的1-脱甲基衍生物（10a-f）。检查了毒素黄素（1a-e），毒素4-氧化物（3a-e）及其6-苯基类似物（7a-f和8a-f）对多种细菌和真菌菌株的活性。大多数化合物显示出对革兰氏阳性细菌的强抑制活性。在化合物中，1c，1d，1e和3c表现出对微球菌的最强抑制作用（0。5微克/毫升的最小生长抑制浓度）和金黄色葡萄球菌4R（1微克/毫升），以及枯草芽孢杆菌和金黄色葡萄球菌（1-2微克/毫升）。大多数化合物对白色念珠菌和酿酒酵母具有很强的抗真菌活性（最低2-100微克/毫升的生长抑制浓度）。
• 3-Furanyl analogs of toxoflavine as kinase inhibitors
  申请人：LaCrampe Armand Jean Fernand

  公开号：US20060040943A1

  公开（公告）日：2006-02-23

  The present invention concerns the compounds of formula the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein m represents an integer being 0 or 1; n represents an integer being 0, 1 or 2; R 1 represents C 1-4 alkyl, C 1-4 alkyl substituted with pyridinyl, phenyl, piperidinyl or piperidinyl substituted with C 1-4 alkyloxycarbonyl; R 2 represents hydrogen or C 1-4 alkyl; R 3 represents hydrogen or C 1-4 alkyl; or R 2 and R 3 taken together with the carbon atom to which they are attached form cyclopentyl or piperidinyl wherein said cyclopentyl or piperidinyl each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from C 1-4 alkyloxycarbonyl, phenylcarbonyl or —C(═NH)—NH 2 ; R 4 represents halo or C 1-4 alkyloxy; R5 represents Het 2 , C 1-4 alkyl substituted with one or where possible more substituents being selected from hydroxy, halo, Het 3 or NR 6 R 7 , or C 1-4 alkyloxy substituted with one or where possible more substituents being selected from Het 4 or —C(═O)-Het 4 ; R 6 and R 7 are each independently selected from hydrogen, C 1-4 alkyl, Het 5 or C 1-4 alkyl substituted with one or where possible more substituents being selected from hydroxy or Het 5 ; Het 2 represents piperazinyl; Het 3 represents a heterocycle selected from morpholinyl, pyrrolidinyl, piperidinyl, or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from C 1-4 alkyl preferably methyl, aminosulfonyl, mono- or di(C 1-4 alkyl)aminosulfonyl, hydroxyC 1-4 alkyloxyC 1-4 alkyl, C 1-4 alkyloxyC 1-4 alkyl or C 1-4 alkyloxy; Het 4 represents a heterocycle selected from morpholinyl or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three C 1-4 alkyl substituents, preferably methyl; Het 5 represents a heterocycle selected from pyridinyl, pyrrolidinyl or piperidinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from aminosulfonyl, C 1-4 alkyloxycarbonyl or mono- or di(C 1-4 alkyl)aminosulfonyl.

  本发明涉及式化合物 其 N-氧化物形式、药学上可接受的加成盐及其立体化学异构形式，其中 m 代表 0 或 1 的整数；n 代表 0、1 或 2 的整数；R 1 代表 C 1-4 烷基、C 1-4 烷基、被吡啶基、苯基、哌啶基或被 C 1-4 烷氧羰基取代的 C 1-4 烷基 2 代表氢或 C 1-4 烷基；R 3 代表氢或 C 1-4 烷基；或 R 2 和 R 3 与它们所连接的碳原子一起形成环戊基或哌啶基，其中所述环戊基或哌啶基可分别独立地被一个或两个或三个取代基所取代，这些取代基分别独立地选自 C 1-4 烷氧羰基、苯基羰基或-C(═NH)-NH 2 ; R 4 代表卤代烃或 C 1-4 烷氧基；R5 代表 Het 2 , C 1-4 被一个或可能有多个取代基取代的烷基，这些取代基选自羟基、卤代、 Het 3 或 NR 6 R 7 或 C 1-4 被一个或可能有多个取代基取代的烷氧基，这些取代基选自 Het 4 或-C(═O)-Het 4 ; R 6 和 R 7 各自独立选自氢、C 1-4 烷基、Het 5 或 C 1-4 被选自羟基或 Het 5 的一个或多个取代基取代的 C 1-4 烷基 5 ；Het 2 代表哌嗪基；Het 3 代表选自吗啉基、吡咯烷基、哌啶基或哌嗪基的杂环，其中所述单环杂环各自独立地可任选被一个或在可能的情况下被两个或三个各自独立地选自 C 1-4 烷基（优选甲基）、氨基磺酰基、单-或二(C-1-4-烷基) 1-4 烷基）氨基磺酰基、羟基 C 1-4 烷氧基 C 1-4 烷基、C 1-4 烷氧基C 1-4 烷基或 C 1-4 烷氧基 4 代表选自吗啉基或哌嗪基的杂环，其中所述单环杂环可各自独立地被一个或两个或三个 C 1-4 烷基取代基，最好是甲基； Het 5 代表选自吡啶基、吡咯烷基或哌啶基的杂环，其中所述单环杂环可分别独立地被一个或两个或三个取代基取代，这些取代基分别独立地选自氨基磺酰基、C 1-4 烷氧羰基或单个或二个（C 1-4 烷基）氨基磺酰基。
• Investigation of 3-aryl-pyrimido[5,4-e][1,2,4]triazine-5,7-diones as small molecule antagonists of β-catenin/TCF transcription
  作者：Jörg Zeller、Anjanette J. Turbiak、Ian A. Powelson、Surin Lee、Duxin Sun、H.D. Hollis Showalter、Eric R. Fearon

  DOI：10.1016/j.bmcl.2013.08.111

  日期：2013.11

  Nearly all colorectal cancers (CRCs) and varied subsets of other cancers have somatic mutations leading to beta-catenin stabilization and increased beta-catenin/TCF transcriptional activity. Inhibition of stabilized beta-catenin in CRC cell lines arrests their growth and highlights the potential of this mechanism for novel cancer therapeutics. We have pursued efforts to develop small molecules that inhibit beta-catenin/TCF transcriptional activity. We used xanthothricin, a known beta-catenin/TCF antagonist of microbial origin, as a lead compound to synthesize related analogues with drug-like features such as low molecular weight and good metabolic stability. We studied a panel of six candidate Wnt/beta-catenin/Tcf-regulated genes and found that two of them (Axin2, Lgr5) were reproducibly activated (9-10 fold) in rat intestinal epithelial cells (IEC-6) following beta-catenin stabilization by Wnt-3a ligand treatment. Two previously reported beta-catenin/TCF antagonists (calphostin C, xanthothricin) and XAV939 (tankyrase antagonist) inhibited Wnt-activated genes in a dose-dependent fashion. We found that four of our compounds also potently inhibited Wnt-mediated activation in the panel of target genes. We investigated the mechanism of action for one of these (8c) and demonstrated these novel small molecules inhibit beta-catenin transcriptional activity by degrading beta-catenin via a proteasome-dependent, but GSK3 beta-, APC-, AXIN2- and beta TrCP-independent, pathway. The data indicate the compounds act at the level of beta-catenin to inhibit Wnt/beta-catenin/TCF function and highlight a robust strategy for assessing the activity of beta-catenin/TCF antagonists. (c) 2013 Elsevier Ltd. All rights reserved.